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Tryptase is involved in proteinase-activated receptor-2 (PAR-2) mediated up-regulation of IL-8 expression. The present report showed the
effects of tryptase on gene expression and activation, including up-regulation IL-8 expression. The expression of mRNA for NF-κB first increased
at 1 h after tryptase-treatment (1 ng/ml) and reached the plateau after 4 h. The NF-κB mRNA increased by 3-fold (n=3, P<0.05), AP-1 by 2-fold
(n=3, P<0.05), and PKB by 10-fold (n=3, P<0.05). However, tryptase-treatment did not affect the expression of JNK and p38 MAPK when
compared with control cells at mRNA level. Furthermore, in addition to increasing phosphorylation of p38 MAPK, tryptase-treatment also
increased phosphorylation of PKB by 2-fold at 15 min following the treatment. The up-regulation and phosphorylation of PKB by tryptase could
be abolished by either phosphoinositol-3-kinase (PI3K) inhibitor (LY294002) at 10 μM or antisense PKB cDNA transfection. The up-regulation of
NF-κB expression could be inhibited by LY294002 and antisense PKB cDNA. These results indicate that tryptase can activate PI3K-PKB
pathway and enhance IL-8 expression.
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Tryptases are the predominant serine proteases of human
mast cells. β-Tryptases appear to be the main isoenzymes
expressed in human lung and skin mast cells whereas in
basophils α-tryptases predominate. [1]. At neutral pH, human
mast cell β-tryptase is stabilized in its enzymatically active,
tetrameric form by heparin, and resists inhibition by biologic
protease inhibitors. After dissociation of β-tryptase from
heparin, active tetramers rapidly convert to inactive monomers
in an isotonic, neutral pH environment. Inactive β-tryptase
monomers can be completely converted to active tetramers at
acidic pH in the absence of heparin [2]. The optimal pH for
tryptase to cleave fibrinogen was also acidic. B12, the anti-
tryptase monoclonal antibody, dramatically enhanced the rate
and extent that tryptase cleaved all three fibrinogen subunits at
pH 6.0 to 6.5, but inhibited these activities at neutral pH. The
acidic pH optimum for tryptase fibrinogenolysis may direct this
activity to tissue sites of inflammation [3]. Tryptase plays an⁎ Corresponding author.
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doi:10.1016/j.bbamcr.2006.02.002important role in many diseases such as allergic rhinitis, asthma,
atherosclerosis, and inflammation [4]. Tryptase can promote the
blood vessel cell proliferation and vascularization, induce the
proliferation of epithelial cell, fibroblast and smooth muscle cell
[5], and facilitate the expression of adhesion molecule, cytokine
and proinflammatory molecule in different cells [6]. Recent
studies suggest that this enzyme is one of the key inflammatory
mediators, and may represent a promising target for therapeutic
intervention [7]. In animal models, injection of purified human
tryptase can induce microvascular leakage [8] and stimulate the
accumulation of eosinophils and neutrophils at the injection
sites [9,10].
Mast cells are found frequently in close proximity to blood
vessels, and endothelial cells are likely to be exposed to high
concentrations of their granule mediators, including tryptase.
Endothelial cells are now recognized as key players in the
process of inflammation. The strategic positioning of the
endothelium between the blood and tissue allows it to regulate
the flow of inflammatory cells to and from a site of
inflammation. Mast cell tryptase can enhance interleukin-
8 production in human endothelial cells, which belongs to the
C–X–C chemokine family. IL-8 is well established as a potent
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cytes, and eosinophils and may also play important roles in
atherogenesis and myocardial ischemia/reperfusion injury
[6,11]. However, the biochemical and cellular events about
IL-8 production by endothelial cells in response to tryptase at
sites of inflammation remain poorly understood.
Previous studies showed that cellular response to tryptase
is mediated by a family of G-protein-coupled and protease-
activated receptors (PARs), which may represent a mecha-
nism related with PAR-2 activation in ECV304 or other
cells [12,13]. PAR-2 is activated by a limited proteolysis at
its amino-terminal exodomain catalyzed by trypsin or
tryptase. Mast cell tryptase may be a pathophysiologically
important activator of PAR-2 in the vasculature, where PAR-
2 induces endothelium-dependent relaxation of arterial rings
and mitogenesis [14,15]. Mast cell infiltration and elevation
of tissue tryptase levels also are characteristic of certain
cardiac syndromes [16,17]. However, the subsequent signal
pathway is unclear.
Studies have identified AP-1 as a potential target of
tryptase [18]. And NF-κB is also involved in cytokine
release induced by PAR-2 in human dermal microvascular
endothelial cells [19]. In myocytes, SLIGRL (an agonist
peptide for PAR-2) stimulates phosphoinositide hydrolysis
and activates the extracellular signal transduction–regulated
protein kinase (ERK) and weakly activate the stress-
activated protein kinase (p38 MAPK). However, PAR-2
does not significantly affect the activation of c-jun N-ter-
minal kinase (JNK) [14]. In astrocytoma cells, activation of
PAR-2 can induce TNFα expression via p38 MAPK and
ERK pathway [20]. In the present study, we found that mast
cell tryptase activated PKB and stimulated the expression of
NF-κB and AP-1 mRNA. These results indicate that tryptase
can induce PI3K-PKB pathway through PAR-2 receptor and
up-regulate IL-8 expression.
2. Materials and methods
2.1. Materials
RPMI1640 and Trizol reagent were purchased from the Gibco (Carlsbad,
CA, USA); Rabbit phospho-PKB (Thr308), phospho-specific p54/p46
MAPK, phospho-specific p38 MAPK and total p38 MAPK antibodies
were obtained from Cell Signaling Co. (Beverly, MA, USA); PI3K inhibitor
LY294002 was from Merck Co. (Whitehouse, NJ, USA). PAR-2 mono-
clonal antibody SAM11, mouse actin antibody and horseradish peroxide-Table 1
The sequences of primers and their denatured temperatures used in PCR
Gene Sense primer Anti-sense prim
IL-8 atgacttccaagctggccgtggct tctcagccctcttca
PKB atgacagcatggagtgtgtg cctcagagacacg
p38 ttcaagggcagcgaccac tgcagggactcgaa
JNK tgcttcttttcttcccaggcc ctgaccatattgatc
c-jun atgactgcaaagatggaaacgacc gatgtgccgttgctg
c-fos gcagactacgaggcgtcatc ttcagcaggttggc
p65 cccatctttgacaatcgtgc ctggcaggtactgg
actin accttcaacaacccagccatgtacg ctgatccacatctgcconjugated rat anti-rabbit antibody were obtained from Santa Cruz Co.
(Santa Cruz, CA, USA); Tryptase was kindly provided by Dr. Shunlin Ren
(Division of Gastroenterology, Virginia Commonwealth University, Rich-
mond, VA, USA); AMV reverse transcriptase, Oligo(dT)15 primer, RNase
and Ribonuclease inhibitor from Promega Co. (Madison, WI, USA). Taq
DNA polymerase, dNTP, and all DNA primers from Sangon Co. (Shanghai,
China). ECV304 cells, the human umbilical vein endothelial cell line, were
obtained from the cell bank of the Chinese Academy of Sciences (Shanghai,
China). The antisense cDNA of human PKBα (pcDNA/PKB) was kindly
provided by Dr. Huili Chen (Department of Biochemistry, Fudan University
Shanghai Medical College, Shanghai, China).
2.2. Cell culture and transfection
ECV304 cells were inoculated in 25 cm2 flasks with RPMI 1640 medium
containing 10% fetal calf serum (FCS), and placed in humidified air incubator
with 5% CO2 at 37 °C. The PKBα constructs were transfected into ECV304
cells using a standard method. Briefly, the cells were harvested in the mid-
logarithmic phase of growth using trypsin to release adherent cells and
centrifuged (for 5 min, 500×g) at 4 °C, then resuspended in 0.5× volume of the
original growth medium. The cells were collect by centrifugation (5 min, 500×g,
4 °C) and resuspended in Eppendorf hypo-osmolality electroporation buffer at
room temperature at a concentration of 2.5×107 cells/ml. The cells were mixed
with plasmid DNA (20 μg), and transferred 400 μl cell suspension into
electroporator using multiporator (Eppendorf) at 260 V, 0.065 s/pulse. The
transfected cells were diluted into 5 ml of RPMI-1640 medium containing 10%
FCS. After 48 h, the transfected cells were transferred to RPMI-1640 medium
without FCS.
2.3. Determination of RNA expressions using RT-PCR analysis
ECV304 cells were treated with tryptase, LY294002, antibody against
PAR-2 or PKB antisense cDNA respectively as indicated in the text. Total
RNA was isolated from cells using TRIzol reagent according to the
manufacturer's protocol. RNA concentration was determined by absorbance
at 260 nm and its integrity was verified by electrophoresis on 1.2% denaturing
agarose gels in the presence of 2.2 M formaldehyde. cDNA was prepared by
reverse transcription using 2 μg of total RNA, Oligo(dT)15 primer, and reverse
transcriptase. In the same cDNA preparation, the targeting genes were
amplified by PCR. The sequences of the oligonucleotide primers used for
cDNA amplification were showed in Table 1. The 50-μl PCR reaction includes
5 μl of previously synthesized cDNA, 20 mM Tris–HCl (pH 8.2), 50 mM KCl,
2 nM MgCl2, 0.2 mM of each dNTP, 0.5 μM of each primer, and 2.5 units of
Taq DNA polymerase. After an initial denaturation step at 94 °C for 5 min; the
PCR profile for genes amplification with 30 cycles was: 94 °C for 1 min,
denature at corresponding temperatures as indicated in Table 2 for 1 min; 72 °C
for 1 min. The prolonged step is at 72 °C for 10 min. After PCR, the amplified
products (10 μl) were separated by electrophoresis on 1.2% agarose gels.
Ethidium bromide-stained bands were photographed under an UV transillumi-
nator. Titration of cDNA into the PCR reaction demonstrated a linear
relationship between the conditions used. The semiquantitative data are
presented as the expression of the indicated gene product in relation to that of
β-actin.er Length (bp) Temperature (°C)
aaaacttct 290 60
gcctt 612 60
gtaggg 269 58
agtggt 420 56
gactggat 264 58
aatctc 541 55
aattcc 338 58
tggagggtgg 703 56
Table 2
The genes expression change with different treatment in ECV304 cells
1 ng/ml tryptase LY294002 Antisense PKB
transfection
Anti-PAR2
antibody
IL-8 ↑2.2±0.8 fold* ↓70.1%±3.5%* ↓83.1%±2.1%* ↓70.4%±1.1%*
PKB ↑10.6±1.2 fold* ↓> 95%±4.25%* ↓> 95%±1.9%* ↓13.1%±3.6%
NF-κB ↑3.1±0.6 fold* ↓> 95%±3.1%* ↓> 95%±1.3%* ↓8.4%±4.8%
↓: decreased ratio(vs. tryptase treated group).
↑: increased ratio(vs. control group).
*P<0.05.
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ECV304 cells were made quiescent by incubation with RPMI-1640
containing 0.1% calf serum for 24 h. Cells were treated with PAR-2 monoclonal
antibody SAM11 at 37 °C in serum-free RPMI-1640 medium for specified
duration as indicated in the text. After treatment, cells were lysed with 500 μl of
ice-cold lyses buffer, including 50 mMTris buffer, pH 7.4, 5 mMEDTA, 50 mM
NaCl, 1% Triton-X 100, 1 mM sodium orthovanadate. Solubilized protein was
centrifuged at 13,000×g in a microfuge (4 °C) for 10 min, and protein
concentrations in supernatants were quantified by BCA method. Proteins
(50 μg) were separated using 8% or 12% SDS-polyacrylamide gel electropho-
resis and transferred to PVDF membranes. Membranes were blocked overnight
at room temperature with phosphate-buffered saline containing 5% non-fat dry
milk and 0.1% Tween-20. The blot was probed with suitable antibodies and
incubated overnight at 4 °C. The specific antibodies (1:1000) were used to detect
phospho-PKB (Thr308), phospho-specific p54/p46 JNK, phospho-specific p38
MAPK and total p38 MAPK, respectively. After incubation with secondary
antibody (horseradish peroxide-conjugate rat anti-rabbit antibody 1:4000), the
specific protein bands were detected by ECL autoradiography. Phosphorylation
of protein kinases B at specific site is required for activation. Therefore,
phosphorylation at the specific site was routinely taken as a measure of protein
kinases B enzymatic activity.
2.5. Statistical analysis
All of the data are expressed as the mean±standard deviation (S.D.)
from at least 3 separate experiments performed in triplicate, unless
otherwise indicated. Statistical significance was assessed by analysis of
variance on untransformed data. Statistical analysis was performed using the
Tukey test and the difference between the means was considered significant
when P≤0.05.Fig. 1. Time dependent of the expressions of transcription factors AP-1 and NF-
κB in ECV304 cell following tryptase treatment. Cells were harvested at the
times as indicated following treatment of tryptase (1 ng/ml). Total RNA (or Poly
A purified total mRNA) were purified as described in Methods and specific
mRNAs were determined by RT-PCR Each lane is the mean±S.D. of three
samples. *Significantly different from control, P<0.05. (A) RT-PCR analysis of
mRNA levels of c-fos and c-jun induced by tryptase. (B) RT-PCR analysis of
NF-κB mRNA level induced by tryptase.3. Results
3.1. Tryptase induced NF-κB and AP-1 mRNA expression in
ECV304 cells
To determine whether NF-κB and AP-1 could be regulated
by tryptase, the mRNA expressions of the signal transduction
elements following tryptase treatment (1 ng/ml) or without
treatment as control in ECV304 cells were determined using
RT-PCR. After preparation of cDNA, agarose gel electropho-
resis analysis of PCR products showed bands with 541 bp for
c-fos, 264 bp for c-jun, and 338 bp for NF-κB respectively, as
expected (Fig. 1). The mRNA levels of factors c-fos, c-jun,
and NF-κB, were significantly increased in the tryptase-
treated ECV304 cells (Fig. 1A, B) compared with those in
control cells (P<0.05). It was different for the response of the
expressions to tryptase treatment that mRNA levels of c-fos
and c-jun increased by 2.3-fold and 2-fold, respectively, at1 h, and returned to baseline at 2 h compared with those in
control cells. In contrast, mRNA level of NF-κB increased by
3-fold and reached a peak at 4 h (Table 2). The results
suggested that NF-κB and AP-1 might be involved in IL-
8 expression induced by tryptase.
3.2. Tryptase induces PKB expression in ECV304 cells
To characterize the mechanism of c-fos, c-jun, and NF-κB
activation, the expressions of JNK, p38 MAPK and PKB were
determined following tryptase treatment. JNK and p38 MAPK
were well believed as protein kinases involved in
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p38 MAPK in ECV304 cells by tryptase (1 ng/ml) were
determined using RT-PCR and compared with those in the
control cells. As shown in Fig. 2A, p38 MAPK and JNK did
not change significantly during tryptase treatment. Interest-
ingly, the expression of PKB dramatically increased like NF-
κB as shown in Fig. 2B. The level of PKB mRNA in tryptase-
treated cells increased by 10-fold and reached the peak at 4 h
compared with those in control cells. These results indicated
that PKB was involved in the regulation of tryptase activated
signal transduction.
3.3. Tryptase induces NF-κB expression by activation of PKB
To test whether PKB regulate the expression of c-fos, c-jun,
and NF-κB in the tryptase (1 ng/ml) treated ECV304 cells,
ECV304 cells were: 1. transfected with PKB antisense cDNA
to inhibit PKB synthesis; 2. pretreated with 10 μM LY294002,
a specified inhibitor of PI3-K, for 1 h to inhibit PKB
activation; or 3. preincubated with monoclonal antibody
against PAR-2 to prevent PAR-2 from tryptase digestion and
activation. As shown in Fig. 3A, the expression of NF-κB was
promoted by tryptase treatment, and >95% of the tryptase-
upregulated expression was suppressed by transfection of PKB
antisense cDNA (P<0.05) or by PI3-K inhibitor LY294002
(P<0.05) but not by antibody against PAR-2 (Fig. 3A). As
shown in Fig. 3B, the expressions of c-fos and c-jun were alsoFig. 2. Time dependent of the expression of protein kinases in ECV304 cells follow
treatment of tryptase (1 ng/ml). Total RNA (or Poly A purified total mRNA) was purif
by RT-PCR. Each lane is the mean±S.D. of three samples. *Significantly differe
p38MAPK induced by tryptase. (B) RT-PCR analysis of mRNA level of PKB inducpromoted by tryptase and the up-regulated expression of c-fos
and c-jun were inhibited by transfection of PKB antisense
cDNA (P<0.05); but not by PI3-K inhibitor LY294002 or
antibody against PAR-2 (Fig. 3B). These results indicated that
PKB could regulate the expression of NF-κB but not c-fos and
c–jun. The tryptase up-regulated expressions of IL-8 and PKB
were suppressed by LY294002, antibody against PAR-2, and
PKB antisense cDNA (Figs. 3A, 4A, and B). The data were
summarized in Table 2. The results strongly suggested that
PAR-2 and PKB were involved in the IL-8 expression induced
by tryptase.
3.4. Tryptase activates PKB by phosphorylation
To validate the role of PKB in the pathway of tryptase
promoting IL-8 expression, we examined the phosphorylation
of PKB by Western blot analysis. As shown in Fig. 5A, 1 ng/ml
tryptase could induce a rapid PKB phosphorylation on Thr308.
The phosphorylation of PKB started to increase as early as
5 min, and reached a peak about 2.3-fold at 15 min.
Phosphorylation at the site was routinely taken as a measure
of PKB enzymic activity. To investigate the role of PAR-2 in
PKB phosphorylation induced by tryptase, ECV304 cells were
pretreated with the PAR-2 antibody (2 μg/ml) for 1 h before
stimulation, and then the cells were treated with tryptase (1 ng/
ml) for 15 min. As shown in Fig. 5B, PKB phosphorylation by
tryptase was dramatically reduced by PAR-2 antibody SAM11.ing tryptase treatment. Cells were harvested at the times as indicated following
ied as described in Materials and methods and specific mRNAs were determined
nt from control, P<0.05. (A) RT-PCR analysis of mRNA levels of JNK and
ed by tryptase.
Fig. 3. The roles of PKB and PAR-2 in the expression of c-fos and c-jun and NF-
κB in ECV304 cells following tryptase treatment. Cells were harvested
following treatment as indicated. Total RNA (or Poly A purified total mRNA)
was purified as described in Materials and methods and specific mRNAs were
determined by RT-PCR. Each lane is the mean±S.D. of three samples.
*Significantly different from tryptase treated cells, P<0.05.1: control group; 2:
cells were treated with 1 ng/ml tryptase for 4 h; 3: antisense PKB cDNA
transfected 48 h, then 1 ng/ml tryptase treated for 4 h; 4: 2 μg/ml PAR-2
antibody pretreated for 1 h, then 1 ng/ml tryptase treated for 4 h; 5: 10 μM
LY294002 pretreated for 1 h, then 1 ng/ml tryptase treated for 4 h. (A) Effect of
PKB inhibitor LY294002 or PKB antisense cDNA transfected and PAR-2
antibody SAM11 on PKB and NF-κB mRNA level in ECV304 cells following
tryptase treatment. (B) Effect of PKB inhibitor LY294002 or PKB antisense
cDNA transfected and PAR-2 antibody SAM11 on c-fos and c-jun mRNA level
in ECV304 cells following tryptase treatment.
Fig. 4. PKB and PAR-2 dependent of the expression of IL-8 in ECV304 cells
following tryptase treatment. Cells were harvested following treatment as
indicated. Total RNA (or Poly A purified total mRNA) was purified as described
in Materials and methods and specific mRNAs were determined by RT-PCR.
Each lane is the mean±S.D. of three samples. *Significantly different from
tryptase treated cells, P<0.05 (A) Comparison of the expression of IL-8 with
and without PAR-2 antibody SAM11 in tryptase treated ECV304 cells. 1:
control group; 2: 1 ng/ml tryptase treated for 4 h; 3: 2 μg/ml PAR-2 antibody
pretreated for 1 h, and then 1 ng/ml tryptase treated for 4 h; (B) comparison of
the expression of IL-8 with and without PKB inhibitor lY294002 or PKB
antisense cDNA transfected in tryptase treated ECV304 cells. 1: control group;
2: 1 ng/ml tryptase treated for 4 h; 3:10 μM Y294002 pretreated for 1 h, then
1 ng/ml tryptase treated for 4 h; 4: antisense PKB cDNA transfected 48 h, then
1 ng/ml tryptase treated for 4 h.
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antibody. These results suggested that tryptase may induce
PKB phosphorylation and promote IL-8 expression in ECV304
cells. PAR-2 as the receptor for tryptase , is probably involved in
the way partly.3.5. Tryptase activates p38 MAPK by phosphorylation
To study MAPK subfamilies in the pathway of tryptase
promoting IL-8 expression, we examined the phosphorylation
of p38 MAPK and JNK by Western blot analysis. As shown in
Fig. 6A, 1 ng/ml tryptase did not cause phosphorylation of c-Jun
N-terminal kinases 1 and 2, but tryptase increase the
phosphorylation of p38 MAPK, one of subfamilies of the
MAPK pathway (Fig. 6B). The phosphorylation of p38 MAPK
started to increase immediately after 5 min, and reached a peak
at 15 min. To investigate the role of PAR-2 in p38 phos-
phorylation induced by tryptase, ECV304 cells were pretreated
with the PAR-2 antibody (2 μg/ml) for 1 h before stimulation,
and then the cells were treated with tryptase (1 ng/ml) for
Fig. 5. Tryptase promote phosphorylation of PKB, and SAM11 inhibit it in
ECV304 cells. Cells were harvested following treatment as indicated. Total
proteins were purified as described in Materials and method and specific protein
was determined by SDS-PAGE andWestern blot. Each lane is the mean±S.D. of
three samples. *Significantly different from control, P<0.05. (A) Influence of
tryptase on PKB phosphorylation in ECV304 cells at different time phase. (B)
Influence of PAR-2 antibody SAM11 on PKB phosphorylation in tryptase-
treated ECV304 cells.
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slightly inhibit the phosphorylation of p38 in ECV304 cells.
4. Discussion
Tryptase plays an important role in inflammatory reaction
and proinflammatory cytokines production. The mechanism
has been studied in many cells. Our experiment showed that
tryptase could activate PKB through its membrane receptor
PAR-2 partly, up-regulate the expression of NF-κB mRNA,
and may promote the expression of chemokine IL-8 in
ECV304 cells, the human umbilical vein endothelial cell
line.
PARs are a family of G-protein-coupled protease-activated
receptors. There are four subsets PAR-1,-2,-3, and -4. PAR-3
and PAR-4 have been studied exclusively in the context of
platelet aggregation; potential functions in other tissues
remain unexplored. PAR-1 is activated by cleavage at its N-
terminal exodomain by thrombin; PAR-2 is activated by alimited proteolysis at its amino-terminal exodomain by trypsin
(but not thrombin) or tryptase. Trypsin can activate PAR-2
and PAR-4, while tryptase can only activate PAR-2 [12].
Antibody SAM11 is an IgG2a monoclonal antibody produced
in mice immunized with the peptide SLIGKVDGTSHVTG,
corresponding to residues 37–50 of the human PAR-2
sequence, which are potential sites of cleavage within the N
terminus of human PAR-2 by tryptase [23]. Further detail
about this antibody is provided elsewhere [24]. These studies
indicate that SAM11 may be a PAR-2-specific neutralizing
antibody. We recently found that PAR-2 is expressed on
ECV304 cells and can be activated by tryptase. The increased
expression of IL-8 induced by tryptase is inhibited by SAM11
[25], indicating that PAR-2 is probably involved in the
tryptase induced inflammatory reaction. Previous researches
showed that PAR-2 stimulated phosphoinositide hydrolysis
and promoted the sequential accumulation of IP3, IP2, and
IP1 in cardiomyocytes. It is possible that tryptase activates
PAR-2, which stimulates phosphoinositide hydrolysis fol-
lowed by activation of its signal transduction pathway.
However some studies also show evidence that tryptase
may not always activate PAR-2 [26] and tryptase also induces
its potent mitogenic effects in cultured dog tracheal smooth
muscle cells via novel proteolytic mechanisms independent
from PAR-2 [27]. Thus PAR-2 may partly be involved in
tryptase-mediated effects.
Tryptase can activate the mitogen-activated protein kinase/
activator protein-1 pathway in human peripheral blood
eosinophils, causing cytokine production and release [18]. In
ECV304 cells, we found that tryptase did not affect the
expression of p38 MAPK and JNK at mRNA level, and that
tryptase did not cause phosphorylation of c-Jun N-terminal
kinases 1 and 2 either. But tryptase induced phosphorylation of
p38 MAPK, one of subfamilies of the MAPK pathway.
Furthermore, PAR-2 antibody SAM11 can inhibit slightly the
phosphorylation of p38 MAPK. These results indicate tryptase
may activate AP-1 through inducing phosphorylation of p38
MAPK in ECV304 cell. MAPKs are upstream activators of AP-
1 [28] MAP kinases signaling pathways influence AP-1 activity
by both increasing the abundance of AP-1 components and by
stimulating their activity directly. p38 MAPK phosphorylates
and activates Elk-1 resulting in enhanced SRE(Serum response
factor)-dependent c-fos expression. p38 MAPK also phosphor-
ylates and activates ATF-2 which can bind TPA-response
elements (TREs) in the c-jun promoter. c-Fos and c-Jun form
heterodimers, bind to AP-1 response elements in gene
promoters and enhance AP-1 binding activity to the DNA
[29]. AP-1 can regulate IL-8 production in many cells [30].
Temkin V has also demonstrated that mast cell mediator
tryptase induces IL-8 production and release in human
peripheral blood eosinophils by the mitogen-activated protein
kinase/AP-1 pathway [18].
PKB is an important protein kinase in organism and its
roles include regulation of glycogen synthesis, cell cycle,
cell growth, cell survival, and protein synthesis [31]. Our
study demonstrated that tryptase induced PKB expression,
phosphorylation, and activation. PKB was reported to be
Fig. 6. Tryptase increases phosphorylation of p38-MAPK, and SAM11 inhibits it in ECV304 cells. Cells were harvested following treatment as indicated. Total
proteins were purified as described in Materials and method and specific protein was determined by SDS-PAGE andWestern blot. Each lane is the mean±S.D. of three
samples. *Significantly different from control, P<0.05. (A) Influence of tryptase on JNK phosphorylation in ECV304 cells at different time phase. (B) Influence of
tryptase on p38-MAPK phosphorylation in ECV304 cells at different time phase. (C) Influence of PAR-2 antibody SAM11 on p38-MAPK phosphorylation in tryptase
treated ECV304 cells.
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[32]. It has been demonstrated that PKB can be activated
independently of PI3-K in response to heat shock [33],
adrenergic receptor agonists such as isoproterenol [34], and
cyclic AMP (cAMP) [35]. We found that inhibitor of PI3-
K inhibited PKB expression, phosphorylation, and activa-
tion. These results strongly suggested that tryptase-induced
PKB expression and phosphorylation depended on PI3-K.
The products of PI3-K, phosphatidyl-3,4,5-triphosphate
(PIP3) and phosphatidyl-3,4-biphosphate (PI-3,4-P2), bind
to the pleckstrin homology (PH) domain of PKB to
localize to plasma membrane and induce PKB activation
by PKB kinase (3-phosphoinositide dependent kinase-1,
PDK-1) via the phosphorylation on Thr308 on PKB[36].
These results are different from those in cardiomyocytes
[12]. In cardiomyocytes, PKB is activated by thrombin and
SFLLRN (an agonist peptide of PAR-2 and PAR4).
Physiological significance of the different protease receptors
in these two different cells is unknown. In our experiment,
PAR-2 antibody SAM11 cannot dramatically inhibit the
expression of PKB mRNA in ECV304 cell, but it inhibitdramatically the PKB phosphorylation, these results may
show tryptase can phosphorylate PKB through PAR-2
receptor, activate PI3K-PKB pathway and subsequently
NF-κB and IL-8 expression. Further studies are required to
determine whether tryptase up-regulated NFκB and PKB
expression by other pathways. PKB is also an upstream
signal transduction element for the MAPK pathway. PKB
can cause signal transduction through activating directly
Ras or through cross-talking with JNK [37,38]. Further
studies are required to determine the relationship between
PKB activation and phosphorylation of p38 MAPK in
ECV304 cell.
NF-κB, c-fos and c-jun can be activated by tryptase in
many cells. In human dermal microvascular endothelial
cells, Agonists of proteinase-activated receptor 2 activate
nuclear transcription factor kappaB and induce cytokine
release [19]. Our study described the up-regulation of their
expressions by tryptase. At the same time PKB could
regulate the expression of NF-κB in ECV304 cells. Classic
nuclear factor-κB (NF-κB) is a heterodimer composed of the
p50 and the RelA/p65 subunits. In unstimulated cells, the
320 Y. Ma et al. / Biochimica et Biophysica Acta 1763 (2006) 313–321majority of NF-κB is found in the cytoplasm associated with
a family of inhibitory molecules known as the IκB s. The
canonical NF-κB activation mechanism involves the phos-
phorylation of IκB on two critical serine residues by the
IκB kinase (IKK) signalsome complex [39]. PKB targets the
transactivation function of NF-κB by stimulating the
transactivation domain of RelA/p65 in a manner that is
dependent on IκB kinaseβ activity and on the mitogen-
activated protein kinase p38 [40]. The up-regulation can
promote its downstream gene expressions such as IL-8.
In summary, Our results show that tryptase could activate
PI3K-PKB pathway through cleaving its membrane receptor
PAR-2, up-regulate the expression of NF-κB and AP-1, which
results in the production of chemokine IL-8 in ECV304 cells.
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